Evidence map›Paper›PMID 39800377›Full record

ArticleJournal for immunotherapy of cancer2025

PD-1 suppresses human CD38

Heng Zhang, Hui Zheng, Yanchun Wang, Cuncun Chen, Ying Tong, Suhong Xie, Xiaolu Ma, Lin Guo, Renquan Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The Role of CD4Cells · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Heng ZhangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0003-2655-6659
Hui ZhengDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanchun WangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Cuncun ChenDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Ying TongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Suhong XieDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaolu MaDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China renquanlu@fudan.edu.cn guolin500@hotamil.com.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China renquanlu@fudan.edu.cn guolin500@hotamil.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-programmed cell death protein 1 (anti-PD-1) antibodies have achieved revolutionary success in cancer therapy. However, the impact of anti-PD-1 therapy on host humoral immunity in humans during cancer immunotherapy requires further investigation.

methodsWe evaluated immunoglobulin titers by ELISA and screened the immune landscape of immune cells from 25 healthy donors and 50 cases including 25 new-onset hepatocellular carcinoma (HCC) patients prior to systemic treatment and 25 HCC patients undergoing anti-PD-1 therapy by multicolor flow cytometry. Flow or beads sorted cells were cultured ex vivo for proliferation and functional analysis.

resultsAnti-PD-1 therapy significantly increased the levels of IgG and IgA in the periphery of HCC patients. Anti-PD-1 treatment led to an increase in plasmablasts and a notable rise in circulating T follicular regulatory (cTfr) cells, while changes in circulating B cells, T follicular helper cells, or regulatory T cells were not significant. Anti-PD-1 therapy also influenced the proliferation and function of cTfr cells, promoting the differentiation of CD38

conclusionsTogether, these data demonstrate the immunomodulatory role of PD-1 in restricting the differentiation and function of human cTfr cells and in regulating humoral immunity.

Indexed as

ADP-ribosyl Cyclase 1Carcinoma, HepatocellularImmunity, HumoralLiver NeoplasmsProgrammed Cell Death 1 ReceptorAdultAgedFemaleHumansMaleMembrane GlycoproteinsMiddle AgedADP-ribosyl Cyclase 1CD38 protein, humanMembrane GlycoproteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorHumoralImmune Checkpoint InhibitorT regulatory cell - Treg

Identifiers

PMID39800377
PMCPMC11748770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.